BioMarin is a speculative Buy as lower valuation, FDA catalysts, and Voxzogo growth potential may reward long-term investors.

About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people ...

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-stage biotech company.

BioMarin Pharmaceutical (BMRN) is back in focus after a mixed Q3 2026 update, with adjusted profit topping analyst ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.12 per share a ...

Biotech company BioMarin Pharmaceutical (NASDAQ: BMRN) met Wall Street’s revenue expectations in Q3 2026, with revenue up 32% ...

BioMarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus ...

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.

BioMarin Pharmaceutical has been busy, with a large acquisition, fresh Fabry disease assets and a stock price that is still ...

Thank you, operator. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding ...

BioMarin Pharmaceutical Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported revenue was USD 1,024.65 million ...

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is steadily carving its niche in the biotechnology sector, particularly in the ...